Elli Papaemmanuil
About Elli Papaemmanuil
Elli Papaemmanuil is the CEO and Scientific Co-founder of Isabl, with extensive expertise in AI applications to precision medicine and a significant academic and professional background in computational biology and oncology.
Elli Papaemmanuil: CEO and Scientific Co-founder
Elli Papaemmanuil holds the titles of CEO and Scientific Co-founder, showcasing her leadership and extensive expertise in the field. She is renowned for her contributions to applying AI in precision medicine, addressing some of the most complex challenges in clinical oncology. Her leadership extends into various roles within the industry, reflecting a comprehensive blend of scientific and business acumen.
Elli Papaemmanuil's Contributions to Precision Medicine
Elli Papaemmanuil is a key opinion leader in the field of precision genomic medicine, notably in clinical oncology. Her work focuses on utilizing advanced computational biology and AI to drive precision medicine initiatives. As the lead developer of the Isabl Platform, she has pioneered new approaches in integrating AI and genomics to improve patient outcomes. Her extensive research and numerous publications in high-impact journals highlight her influence and thought leadership in this area.
Publications by Elli Papaemmanuil
Elli Papaemmanuil has a prolific record of publications in prestigious journals such as the New England Journal of Medicine (NEJM), Nature Genetics, and Nature Medicine. These publications underscore her contributions to understanding and innovating within biomedical and computational biology fields. Her work frequently addresses cutting-edge topics in precision medicine, further cementing her reputation as a leading researcher.
Leadership Roles of Elli Papaemmanuil
In addition to her scientific contributions, Elli Papaemmanuil holds significant leadership roles. She is the Chair of the Department of Pediatrics at Memorial Sloan Kettering and the Director for Cancer Genome Discovery at Dana-Farber Cancer Institute. She also serves in multiple capacities at Isabl, including Director of Operations, Chief Business Officer (acting), Computational Biology Engineer, Computational Biologist, and Computational Biology Consultant. These roles reflect her strategic vision and multidisciplinary expertise in oncology and precision medicine.
Elli Papaemmanuil's Academic and Research Positions
Elli Papaemmanuil is a Biomedical and Software Engineer, and a Professor of Pathology and Genetics at Harvard Medical School. Her academic roles are complemented by her position as a Director at the Dana-Farber Cancer Institute, where she focuses on cancer genome discovery. As a co-founder of Foundation Medicine, she has established a strong foundation in genomics research, earning an h-index of approximately 220, a testament to her impactful and widely-cited research.